How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Uterine Fibroid Embolization Agents Market
- By Embolization Agent Type: Polyvinyl Alcohol (PVA) Particles, Tris-acryl Gelatin Microspheres, Calibrated Microspheres, Hydrogel Microspheres, Non-spherical PVA Particles
- By Particle Size: 100-300 microns, 300-500 microns, 500-700 microns, 700-900 microns, 900-1200 microns
- By Application: Uterine Fibroid Embolization (UFE), Other Gynecological Embolization Procedures
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Polyvinyl Alcohol (PVA) Particles leads By Embolization Agent Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 258 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.162 →
- 11 Company Profiles 10 players: SWOT & benchmarking p.170 →
Full report · locked preview
Everything inside the Uterine Fibroid Embolization Agents Market report
A complete, evidence-based study - 11 chapters and 108 sections covering market size, segmentation across 4 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Embolization Agent Type 5
Particle Size 5
Application 2
End User 3
Companies profiled
Terumo Corporation
Boston Scientific Corporation
Cook Medical (a subsidiary of Cook Group)
Merit Medical Systems Inc.
Biosphere Medical
Beijing Biosis Healing Medical Technology Co. Ltd.
Biocompatibles UK Ltd. (a BTG International group company)
Stryker Corporation
CeloNova Biosciences Inc.
Guerbet Group
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Cook Medical (a subsidiary of Cook Group)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Merit Medical Systems Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Biosphere Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Beijing Biosis Healing Medical Technology Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Biocompatibles UK Ltd. (a BTG International group company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Stryker Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →CeloNova Biosciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Guerbet Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,854M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Polyvinyl Alcohol (PVA) Particles44.8
- Tris-acryl Gelatin Microspheres15.4
- Calibrated Microspheres13.1
- Hydrogel Microspheres17.0
- Non-spherical PVA Particles9.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,487M → $2,108M · 4.5%
Europe$1,036M → $1,402M · 3.9%
Asia Pacific$946.0M → $1,328M · 4.3%
Latin America$585.6M → $840.4M · 4.6%
Middle East and Africa$450.5M → $690.4M · 5.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.352026
5.352027
5.372028
5.382029
5.382030
5.402031
5.412032
5.412033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Terumo Corporation18.6
- Boston Scientific Corporation18.3
- Cook Medical (a subsidiary of Cook Group)10.0
- Merit Medical Systems Inc.5.4
- Biosphere Medical8.9
- Beijing Biosis Healing Medical Technology Co. Ltd.10.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Embolization Agent Type24.9%
Particle Size27.7%
Application19.1%
End User28.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe22.0
- Asia Pacific20.9
- Latin America13.2
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Terumo Corporation | 86 | 97 | 81 | 76 | 93 | 76 | 85 |
| Boston Scientific Corporation | 73 | 80 | 86 | 72 | 69 | 92 | 79 |
| Cook Medical (a subsidiary of Cook Group) | 74 | 69 | 81 | 66 | 72 | 71 | 72 |
| Merit Medical Systems Inc. | 81 | 68 | 77 | 63 | 77 | 67 | 72 |
| Biosphere Medical | 63 | 70 | 55 | 77 | 62 | 54 | 64 |
| Beijing Biosis Healing Medical Technology Co. Ltd. | 52 | 63 | 66 | 63 | 59 | 71 | 62 |
| Biocompatibles UK Ltd. (a BTG International group company) | 52 | 63 | 42 | 43 | 50 | 59 | 52 |
| Stryker Corporation | 52 | 50 | 38 | 40 | 57 | 55 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Terumo Corporation
- Boston Scientific Corporation
- Cook Medical (a subsidiary of Cook Group)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Terumo Corporation | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Boston Scientific Corporation | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Cook Medical (a subsidiary of Cook Group) | ✓ | ◐ | ◐ | − | ◐ | ◐ |
| Merit Medical Systems Inc. | ✓ | − | ◐ | ◐ | ◐ | ✓ |
| Biosphere Medical | ◐ | ◐ | − | ✓ | ◐ | − |
| Beijing Biosis Healing Medical Technology Co. Ltd. | − | − | ◐ | ◐ | − | ◐ |
| Biocompatibles UK Ltd. (a BTG International group company) | ◐ | ◐ | − | ◐ | − | − |
| Stryker Corporation | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Terumo Corporation85
2Boston Scientific Corporation79
3Cook Medical (a subsidiary of Cook Group)72
4Merit Medical Systems Inc.72
5Biosphere Medical64
6Beijing Biosis Healing Medical Technology Co. Ltd.62
7Biocompatibles UK Ltd. (a BTG International group company)52
8Stryker Corporation49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Terumo CorporationBoston Scientific Corporation
Challenger2
Strong scale, closing on the leaders.
Cook Medical (a subsidiary of Cook Group)Merit Medical Systems Inc.
Contender2
Focused players with pockets of strength.
Biosphere MedicalBeijing Biosis Healing Medical Technology Co. Ltd.
Niche2
Specialists in a single segment or region.
Biocompatibles UK Ltd. (a BTG International group company)Stryker Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Embolization Agent Type in North America, then scale across Uterine Fibroid Embolization Agents Market — a $523M beachhead inside a $8.29B market.
Beachhead (SOM)$523Mobtainable near-term
Serviceable (SAM)$3.18Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Polyvinyl Alcohol (PVA) Particles
Best fit — highest urgency & budget in Embolization Agent Type.
Economic buyer76 fit
Tris-acryl Gelatin Microspheres
Strong fit — clear ROI and a fast path to value.
End user66 fit
Calibrated Microspheres
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Embolization Agent Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Particle Size & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel29%
Digital / self-serve18%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Embolization Agent Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Uterine Fibroid Embolization Agents Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified24%
Evaluation15%
Closed-won6%
$21.2KCAC
$84KLTV
3.9:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Uterine Fibroid Embolization Agents Market is a resilient opportunity — $1.97B by 2033, compounding at 5.7%.
TAM · 2025$1.26Btoday
TAM · 2033$1.97Bforecast
CAGR5.7%2027–2033
Cumulative$14.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.97BTotal addressable market
SAM$729MServiceable available market
SOM$123MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.7% CAGR
Demand compounds through 2033, outpacing GDP across Embolization Agent Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Embolization Agent Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.97BLarge & growingTAM by 2033 at 5.7% CAGR
$729MServiceable nowreachable with today’s model
$123MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.53BBear3.7% CAGR
$1.97BBase5.7% CAGR
$2.52BBull7.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Particle Size optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Uterine Fibroid Embolization Agents Market — a $3.25B market by 2033. Plan: grow share from 8.9% to 14.3%.
Market size · 2033$3.25Btotal addressable
Market CAGR8.9%2027–2033
Target share14.3%from 8.9% today
Revenue ambition$465Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.9% | 14.3% | Ahead |
| Revenue | $315M | $465M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 32.1% | 45.7% | Ahead |
| Customer retention | 86.6% | 95.8% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Embolization Agent Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Particle Size capability
A defensible second engine — invest in Particle Size to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Embolization Agent Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Particle Size
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $49M capacity & capability investment
- Greenlight bolt-on M&A in Particle Size
- Authorise North America expansion plan
- Fund R&D program for Embolization Agent Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Uterine Fibroid Embolization Agents Market conversation — a $3.19B market you can size, segment and defend in minutes.
Market size · 2033$3.19Btotal opportunity
Growth5.5%CAGR to 2033
Addressable buyers928+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Embolization Agent Type
Goal Grow share in Embolization Agent Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 4 mopayback period
$64K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Terumo CorporationBoston Scientific CorporationCook Medical (a subsidiary of Cook Group)Merit Medical Systems Inc.Biosphere MedicalBeijing Biosis Healing Medical Technology Co. Ltd.Biocompatibles UK Ltd. (a BTG International group company)Stryker Corporation+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Uterine Fibroid Embolization Agents Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Uterine Fibroid Embolization Agents Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →High Sensitivity C-Reactive Protein Test Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportUsher Syndrome Threapeutics Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportGelatin Peptide Plasma Substitute Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportTyrosine Protein Kinase Receptor TYRO3 Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportTyrosine Protein Kinase Lyn Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportTyrosine Protein Kinase ITK Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportTyrosine Protein Kinase Fyn Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportTyrosine Protein Kinase CSK Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportTyrosinase Market
Market size, share, segmentation and regional forecast.
$484M market · 2025 base year
View reportType 1 Diabetes Drugs Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportTransmembrane Prolyl 4 Hydroxylase Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportTransient Receptor Potential Cation Channel Subfamily V Member 1 Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.